Latest Hematopoietic stem cell Stories
By using OP9-DL1 cells as a support system, researchers can study the differentiation of embryonic stem cells into mature components of the immune system. This month's issue of Cold Spring Harbor Protocols (www.cshprotocols.org/TOCs/toc2_09.dtl) features a set of methods from Juan Carlos Zúñiga-Pflücker's laboratory at the University of Toronto (http://www.immunology.utoronto.ca/faculty/directory/zunigapflucker.htm) detailing "The OP9-DL1 System: Generation of T-Lymphocytes from...
 A new study sheds light on a little understood biological process called quiescence, which enables blood-forming stem cells to exist in a dormant or inactive state in which they are not growing or dividing. According to the study's findings, researchers identified the genetic pathway used to maintain a cell's quiescence, a state that allows bone marrow cells to escape the lethal effects of standard cancer treatments.Researchers at Memorial Sloan-Kettering Cancer Center (MSKCC) found...
A type of stem cell responsible for all blood and immune system cells reproduces much more slowly than expected.Using this subpopulation of hematopoietic stem cells may help treatment of leukemia and other marrow-based diseases by improving the outcome of stem cell transplants, also referred to as bone marrow transplants.The entire population of hematopoietic stem cells (HSCs) in bone marrow are believed to reproduce at a rate of about 7 percent per day, with each cell dividing every two...
BOTHELL, Wash., Dec. 29 /PRNewswire-FirstCall/ -- CellCyte Genetics Corporation (CellCyte) (OTC Bulletin Board: CCYG) reports that a December 24, 2008 article published by the Seattle Times reporting on CellCyte's third quarter 2008 SEC 10Q filing incorrectly reported that CellCyte 'closes.' In CellCyte's August 14, 2008 press release, the Company reported progress in its bioreactor business segment and generally described its development plan to commercialize its bioreactor product line....
 Using stem cell lines not typically combined, researchers at Columbia University Medical Center have designed a new way to "grow" bone and other tissues.The inability to foster angiogenesis "“ a physiological process involving the growth of new blood vessels from pre-existing vessels "“ has been a major roadblock in tissue regeneration. Previous approaches have included the use of angiogenic growth factors and the fabrication of artificial blood vessels. However, there are...
Investigators from Massachusetts General Hospital (MGH) have found a subpopulation of hematopoietic stem cells, the source of all blood and immune system cells, that reproduce much more slowly than previously anticipated. Use of these cells may improve the outcome of stem cell transplants "“ also called bone marrow transplants "“ for the treatment of leukemia and other marrow-based diseases. The report will appear in the journal Nature Biotechnology and is being released online to...
Stem cells derived from bone marrow may serve as a novel therapeutic option to treat a disease called epidermolysis bullosa (EB), a disorder characterized by extraordinarily fragile skin, according to a study prepublished online in Blood, the official journal of the American Society of Hematology.Epidermolysis bullosa is a disorder characterized by extraordinarily fragile skin and blistering on touch, akin to third degree burns. While the disease is often lethal in the neonatal period, more...
International Stem Cell Corporation (OTCBB:ISCO) (www.internationalstemcell.com), a California-based, early-stage stem cell therapeutics company, announced today that Rouslan Semechkin has joined its Board of Directors. International Stem Cell Corporation's focus is on the development of stem cell based treatment of diabetes, liver disease and diseases of the retina and providing specialized cells and media to others for cell based research. It maintains corporate and research facilities...
A family of cancer-fighting molecules helps blood stem cells in mice decide when and how to divide, say researchers at the Stanford University School of Medicine. Blocking the molecules' function spurs the normally resting cells to begin proliferating strangely -- making too much of one kind of cell and not enough of another. Many types of human blood cancers involve a similar disruption in the expression of that same family of molecules. The blood stem cells' misguided enthusiasm also...
International Stem Cell Corporation (OTCBB: ISCO) has entered into a subscription agreement with an accredited investor to sell three million dollars ($3,000,000) of Series C Preferred Stock at a price of $1.00 per share. The funding is to occur in three tranches. The first, for $700,000, closed August 20, 2008. The second closing for $1,300,000 is scheduled for September 23, 2008 and the final closing of $1,000,000 is scheduled for December 15, 2008, subject to determination by the investor...
